

My-DST Drug Assay to Optimize Therapy for Multiple Myeloma

Lyndsey R. Babcock¹, Lauren T. Reiman¹, Zachary J. Walker¹, Peter A. Forsberg¹, Daniel W. Sherbenou^{1,2} and Tomer M. Mark¹

¹Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ²University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.



Background

- Multiple Myeloma is a malignancy of plasma cells accounting for ~10% of all hematologic cancers.¹
- ~32,000 new cases of myeloma are diagnosed each year in the United States.²
- Therapy has evolved from traditional chemotherapy to monoclonal antibodies, proteasome inhibitors, and immunomodulatory agents, often in addition to autologous stem cell transplant.³⁻⁵
- Treatment outcomes have improved but these new treatments are also associated with potential toxicities and significant cost.
- Personalized treatment can be more efficacious and potentially avoid unnecessary side effects and costs.
- Multiple myeloma has broad genetic heterogeneity, many oncogenic drivers, and no targetable gene product making precision medicine challenging.
- Taking a phenotypic approach using *ex vivo* drug sensitivity profiling of tumor samples may lead to targeted personalized therapy, using only active agents, to minimize cost and toxicities.

My-DST




Figure 1: My-DST schematic

- My-DST is an *ex-vivo* drug sensitivity assay that tests agents used to treat multiple myeloma against patient's cells.
- First, a patient's bone marrow aspirate undergoes mononuclear cell selection.
- Cells are then treated with a panel of anti-myeloma drugs and screened for plasma cell survival using flow cytometry.
- Drugs with greater than 20% cell killing are estimated to be active agents.

Patient Case: 72 y.o. Male

- First developed back pain in sacrum radiating down both legs
- Lumbar x-ray suspicious for lytic bone lesion. Spine MRI with multi-level metastatic disease
- Biopsy of L5 lesion suggestive of plasma cell neoplasm
- Presented to AMC blood disorders clinic for eval and workup
- Diagnosed with IgA-lambda multiple myeloma with lytic bone disease
- ISS stage 1, R-ISS 1, SD 3a, normal karyotype, del13q (std risk)
- My-DST was performed on a sample donated by the patient which showed resistance to immunomodulatory drugs but sensitivity to proteasome inhibitors
- He was treated with four total lines of therapy (see table below)
- As predicted by My-DST, he had a minimal response (MR) to the immunomodulatory agent Lenalidomide, but quickly achieved a very good partial response (VGPR) using bortezomib (proteasome inhibitor) and dexamethasone.

Line of Therapy	Response
1. Lenalidomide + Dexamethasone (Rd)	MR
2. Bortezomib + Dexamethasone (Vd)	VGPR → PoD
3. Elotuzumab + Revlimid + Dexamethasone (EloRd)	PR → PoD
4. Elotuzumab + Pomalidomide + Dexamethasone (EloPd)	PR

Figure 2: Lines of therapy patient received and corresponding response. MR: minimal response, VGPR: very good partial response, PR: partial response, PoD: progression of disease.




Figure 3: (A) My-DST results from patient sample at time of diagnosis. 81% viable myeloma cells after lenalidomide exposure and only 15% viable after bortezomib. (B) Patient response for line one and two of treatment based on serum free light chains.

Discussion

- Patients with multiple myeloma eventually relapse and become resistant to treatment.
- There are now many treatment choices, but response and side effects are often unpredictable.
- With multiple myeloma which affects primarily older patients with a median onset of 70 years, frailty and comorbidities are also important when discussing toxic treatments.¹
- Elderly and frail patients are sometimes undertreated or overtreated leading to worse clinical outcomes. Personalized therapies and better drug selection may improve the response for this population.⁶
- This patient case demonstrates the potential benefit of personalized medicine in multiple myeloma treatment as the clinical course corresponded with *ex vivo* sensitivities.
- My-DST may be one method to improve outcomes for multiple myeloma through a more personalized approach.

Conclusions

- Multiple myeloma is a heterogeneous hematologic malignancy with an expanding array of treatments.
- A more optimized/personalized therapy selection approach would reduce exposure to potentially harmful agents with side effects, eliminate wasted time from ineffective agents, and reduce costs.
- This patient case was consistent with the My-DST assay results as he had an inadequate response to lenalidomide/dexamethasone but achieved a very good partial response when switched to bortezomib/dexamethasone.
- Further studies with My-DST need to be done to further evaluate the success of phenotypic-based therapy.

References

- Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364(11):1046-1060. doi:10.1056/NEJMra1011442
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590
- Brenner H, Gonsky A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521-2526. doi:10.1182/blood-2007-08-104984
- Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1(4):282-287. doi:10.1182/bloodadvances.2016002493
- Krok-Schoen JL, Fisher JL, Stephens JA, et al. Incidence and survival of hematological cancers
- Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519-4529. doi:10.1182/blood-2011-06-358812
- among adults ages ≥75 years. Cancer Med. 2018;7(7):3425-3433. doi:10.1002/cam4.1461

Acknowledgements

- Thank you to the patients who donated samples for the development of My-DST.
- This work was supported by grants from the Colorado Clinical & Translational Sciences Institute (Junior Faculty CO-Pilot Award, NIH/NCATS Colorado CTSA Grant Number UL1 TR002535) to D.W.S., the National Comprehensive Cancer Network (NCCN) Foundation (2016 Young Investigator Award) to D.W.S. and the National Cancer Institute (K08CA222704) to D.W.S. The authors would like to thank the Hematology Clinical Trials Unit at the University of Colorado for tissue bank and regulatory support.